This Week’s CGT News: New FDA Genome Editing Guidance  - Summary - MDSpire
Clinical Guidelines
Feature

This Week’s CGT News: New FDA Genome Editing Guidance 

Our latest roundup highlights tighter FDA expectations for genome editing safety, advances in CRISPR precision and delivery, and continued momentum for off-the-shelf CAR-T

  • April 20, 2026

  • 6 min

Share

The FDA has issued draft guidance on genome editing safety, emphasizing the importance of next-generation sequencing (NGS) for assessing gene therapies. Highlights include recommendations for study design, sequencing strategies, and analytical approaches to detect off-target effects and ensure genome integrity. Concurrently, Allogene Therapeutics reports promising results from its CAR-T therapy, cemacabtagene ansegedleucel (cema-cel), showing high minimal residual disease (MRD) clearance rates in lymphoma patients. Long-term follow-up protocols for CAR-T therapy are under review due to a lack of adverse events reported beyond three years. Innovative CRISPR technologies have emerged for cancer treatment, employing methylation patterns for precision targeting and optimizing AAV delivery.

Original Source(s)

This Week’s CGT News: New FDA Genome Editing Guidance 

  • April 20, 2026

Related Content

This Week’s Biopharma News: KRAS Breakthrough and ADC Momentum

Revolution’s KRAS breakthrough, strong ADC signals from GSK, and shifting regulatory and dealmaking dynamics define this week in biopharma

  • April 21, 2026

  • 4 min
Modeling the Genetics of Uveal Melanoma

Researchers have developed a genetically engineered mouse model that mirrors the genetic evolution of uveal melanoma

  • April 21, 2026

  • 3 min
‘Prostate Screening Saved My Life’—Is That Really True in Most Cases?

Prostate specific antigen (PSA) screening remains one of the most controversial of “standard” medical practices. As recently as the 2026 Super Bowl, one of the more unusual TV advertisements, sponsore...